{"product_id":"cst-79395s","title":"CST,  79395S, Total ROS1 Matched Antibody Pair","description":"Matched Antibody Pair for studying ROS in the research area.\n\n\u003cb\u003eProduct Usage Information\u003c\/b\u003e\nMatched Antibody Pairs consist of capture and detection antibodies that bind to non-overlapping epitopes. For specific identification of the capture and detection antibodies in this pair, please refer to the data figure caption. Optimal dilutions\/concentrations should be determined by the end user.\n\u003cb\u003eFormulation\u003c\/b\u003e\nSupplied in 1X PBS (10 mM Na 2 HPO 4 , 3 mM KCl, 2 mM KH 2 PO 4 , and 140 mM NaCl (pH 7.8)). BSA and Azide Free.\n\u003cb\u003eStorage\u003c\/b\u003e\nStore at -20ºC. This product will freeze at -20ºC so it is recommended to aliquot into single-use vials to avoid multiple freeze\/thaw cycles . A slight precipitate may be present and can be dissolved by gently vortexing. This will not interfere with antibody performance.\n\u003cb\u003eBackground\u003c\/b\u003e\nROS1, an orphan receptor tyrosine kinase of the insulin receptor family, was initially identified as a homolog of v-ros from the UR2 sarcoma virus (1). ROS1 consists of a large extracellular domain that is composed of six fibronectin repeats, a transmembrane domain, and a C-terminal kinase domain. Being an orphan receptor, the functions of ROS1 are not well known, though it has been shown to play an important role in differentiation of epididymal epithelium (2). The first oncogenic fusion of ROS1, FIG-ROS1, was initially identified by research studies in glioblastoma (3), and subsequent studies have found this fusion in cholangiocarcinoma (4), ovarian cancer (5), and non-small cell lung cancer (NSCLC) (6). Investigators have found additional oncogenic ROS1 fusion proteins in NSCLC (at a frequency of ~1.6%), where the ROS1 kinase domain is fused to the amino-terminal region of several different proteins, including CD74 and SLC34A2 (6-8). ROS1 fusion proteins activate the SHP-2 phosphatase, PI3K\/Akt\/mTOR, Erk, and Stat3 pathways (3,4,9). There are two autophosphorylation sites (Tyr2274, Tyr2334) downstream of the kinase domain of ROS1, either of which may serve as biomarkers of ROS1 kinase activity, including that of ROS1 fusion proteins (10).\n\u003cb\u003eAlternate Names\u003c\/b\u003e\nc-ros oncogene 1 , receptor tyrosine kinase; c-Ros receptor tyrosine kinase; c-ros-1; MCF3; Proto-oncogene c-Ros; Proto-oncogene c-Ros-1; proto-oncogene c-ros-1 protein; Proto-oncogene tyrosine-protein kinase ROS; Receptor tyrosine kinase c-ros oncogene 1; ROS; ROS proto-oncogene 1 , receptor tyrosine kinase; ROS proto-oncogene 1, receptor tyrosine kinase; ROS1; transmembrane tyrosine-specific protein kinase; v-ros avian UR2 sarcoma virus oncogene homolog 1; v-ros UR2 sarcoma virus oncogene homolog 1\n\n\u003cb\u003eSpecification\u003c\/b\u003e\n\nREACTIVITY: H","brand":"CST","offers":[{"title":"Default Title","offer_id":46800322232489,"sku":"79395S","price":0.99,"currency_code":"USD","in_stock":true}],"url":"https:\/\/iright.com\/products\/cst-79395s","provider":"Iright","version":"1.0","type":"link"}